All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
On December 21, 2020, it was announced that the phase III LACEWING trial (NCT02752035) failed to meet its primary endpoint of a statistically significant improvement in overall survival with gilteritinib plus azacitidine, versus azacitidine alone, in patients with newly diagnosed, FLT3-mutated acute myeloid leukemia (AML), who were ineligible for intensive induction chemotherapy.1
Based on the results of this planned interim analysis, an independent data monitoring committee recommended terminating the study. Therefore, enrolment to the trial has ceased. A thorough review of the data has commenced, with results to be published in due course.1
Treatment of older or unfit patients with AML
Prof. Courtney DiNardo, MD Anderson Cancer Center, Houston, US, discussed the optimal treatment strategy for elderly or frail patients with AML at the 1st NCRI AML academy.
Charles Craddock | EBMT 2019 | Optimization of the graft-versus-leukemia effect
At the 45th Annual Meeting of the EBMT, Charles Craddock talks about optimizing the graft-versus-leukemia effect
Subscribe to get the best content related to AML delivered to your inbox